Molecular Profiling Technologies

Caris Life Sciences® offers unique precision medicine services that are designed to maximize the chances of success for clinical trials and address many patient accrual challenges facing biopharma partners in the world of precision medicine.​

Caris Molecular Testing - Complete Gene Coverage

As the pioneer in precision medicine, Caris was the first to provide Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) for every patient. All molecular profiling orders include next-generation sequencing of all 22,000 genes.

icon_DNA

Whole Exome Sequencing (WES) DNA

  • 22,000 genes
  • 800x read count for clinical genes
  • SNVs, indels, copy number alterations & Karyotyping
  • 250,000 evenly-spaced genomic SNP
  • Genomic signatures:
    • Homologous Recombination Deficiency* (HRD)
    • Genomic Loss of Heterozygosity (gLOH)
    • Microsatellite Instability (MSI)
    • Tumor Mutational Burden (TMB)
  • Other:
    • HLA Genotype*
icon_RNA

Whole Transcriptome Sequencing (WTS) RNA

  • 22,000 genes
  • 23Mx read count
  • Gene fusions, variant transcripts & gene expression
  • Novel translocation detection independent of intronic breakpoint

Caris Molecular Profiling Menu by Region

international-caris-sm-ol-co.svg

International & US

Review and download the Caris molecular profiling testing menu for US and International cases.

Download
new-york-caris-sm-ol-co.svg

New York

Review and download the Caris molecular profiling testing menu for New York state cases.

Download
europe-caris-sm-ol-co.svg

European Union (EU)

Review and download the Caris molecular profiling testing menu for European cases.

Download

Caris Molecular Profiling Menu by Region

international-caris-sm-ol-co.svg

International & US

Review and download the Caris molecular profiling testing menu for US and International cases.
new-york-caris-sm-ol-co.svg

New York

Review and download the Caris molecular profiling testing menu for New York state cases.
europe-caris-sm-ol-co.svg

European Union (EU)

Review and download the Caris molecular profiling testing menu for European cases.

Comprehensive Tumor Profiling Technologies

Caris uses the most advanced technologies for biomarker identification, allowing our medical teams to understand fully the biology of the tumor, which helps oncologists plan the best treatment strategy.

  • Next-Generation Sequencing (NGS): Caris has one of the most advanced sequencing laboratories in the world, enabling Whole Exome (DNA) and Whole Transcriptome (RNA) sequencing on every patient.
  • Immunohistochemistry (IHC): Caris evaluates protein biomarkers through an extensive immunohistochemical panel analyzed in a tumor-type specific manner to conserve tissue and avoid unnecessary testing. Our large team of board-certified expert pathologists utilizes digital pathology, overseeing application and interpretation of this technology.
  • In situ Hybridization (ISH): For select genes, we offer ISH to provide higher level of resolution to our IHC results to detect amplification.
  • Pyrosequencing (PyroSeq): We offer methylation analysis of the MGMT promoter to guide therapy selection in glioma.
  • Microdissection: The Caris Pathology team reviews every sample prepared for DNA and RNA sequencing and performs microdissection on every specimen, which results in a significant enrichment of the sample for DNA and RNA derived from the tumor. Because of this process, we are able to provide results in more than 95% of the cases and are able to detect molecular sub-clones present in the tumor.

*Not available in all locations.

Please complete the form below to have a Caris Scientific Rep (Medical Science Liaison) contact you directly.

"*" indicates required fields

Name*
Preferred contact method*

Order Profiling

Place an order today for a comprehensive, personalized Caris profiling report.